GlassScriptPhysician profile
Megan M Early
NPI 1720581531
$2,218.50
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $171 · 2022: $1,318 · 2023: $729.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $635 · Education: $94.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $635.36 |
| Education | $94.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $692.37 | 2021-2023 | Vraylar, Ubrelvy, Linzess |
| Novo Nordisk INC | $445.59 | 2021-2023 | Ozempic, Rybelsus |
| Abbott Laboratories | $278.23 | 2021-2023 | Freestyle Libre 2, Freestyle Libre 3 |
| Astellas Pharma US INC | $172.49 | 2022-2023 | Veozah |
| Biohaven Pharmaceutical Holding Company LTD. | $166.55 | 2022 | |
| Glaxosmithkline, LLC. | $104.84 | 2022-2023 | Arexvy, Shingrix |
| Bayer Healthcare Pharmaceuticals INC. | $95.75 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $43.12 | 2022-2023 | Breztri, Farxiga |
| Nestle Healthcare Nutrition INC. | $36.80 | 2022-2023 | |
| Gilead Sciences, INC. | $35.54 | 2022-2023 | |
| Avanir Pharmaceuticals, INC. | $30.97 | 2022 | |
| Lilly USA, LLC | $28.79 | 2022-2023 | Mounjaro |
| Dexcom, INC. | $23.58 | 2023 | Dexcom G6 Transmitter |
| Viiv Healthcare Company | $22.50 | 2023 | Apretude |
| Biohaven Pharmaceuticals, INC. | $15.85 | 2021 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $13.74 | 2023 | |
| Amgen INC. | $11.79 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Megan Early listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.